Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Phase II Crossover Study of GT-02037 vs Octreotide in Japanese Patients With Acromegaly
jRCT2061220037Phase 2Active, not recruiting
- Sponsor
- GlyTech
- Start
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GT-02037 in acromegaly (2 arms), sponsored by GlyTech. Primary endpoint: Maximal reduction rate in blood GH level. Started Nov 2022; status: active, not recruiting.
02
Drugs
GT-02037
03
Conditions
acromegaly
Beyond the preview
Go deeper on jRCT2061220037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220037.